NKTR - Nektar Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

NKTR is currently covered by 6 analysts with an average price target of $27.61. This is a potential upside of $5.86 (26.94%) from yesterday's end of day stock price of $21.75.

Nektar Therapeutics's activity chart (see below) currently has 136 price targets and 95 ratings on display. The stock rating distribution of NKTR is 57.14% HOLD, 28.57% BUY and 14.29% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 68.34% with an average time for these price targets to be met of 380.44 days.

Highest price target for NKTR is $6, Lowest price target is $2, average price target is $4.

Most recent stock forecast was given by ROGER SONG from JEFFERIES on 11-Apr-2025. First documented stock forecast 28-Jul-2014.

Currently out of the existing stock ratings of NKTR, 4 are a HOLD (57.14%), 2 are a BUY (28.57%), 1 are a SELL (14.29%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$2

$-19.75 (-90.80%)

$1.6

3 months 30 days ago
(11-Apr-2025)

5/5 (100%)

$1.38 (222.58%)

39

Hold

$6

$-15.75 (-72.41%)

$3

4 months 27 days ago
(14-Mar-2025)

6/6 (100%)

$5.1 (566.67%)

374

Buy

$4

$-17.75 (-81.61%)

10 months 11 days ago
(30-Sep-2024)

3/6 (50%)

$2.7 (207.69%)

186

Sell

1 years 8 months 21 days ago
(20-Nov-2023)

7/8 (87.5%)

$6.02 (54.83%)

509

Buy

$2

1 years 9 months 1 days ago
(09-Nov-2023)

3/4 (75%)

$0.61 (43.88%)

1372

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NKTR (Nektar Therapeutics) average time for price targets to be met?

On average it took 380.44 days on average for the stock forecasts to be realized with a an average price target met ratio 68.34

Which analyst has the current highest performing score on NKTR (Nektar Therapeutics) with a proven track record?

JOSH SCHIMMER

Which analyst has the most public recommendations on NKTR (Nektar Therapeutics)?

Josh Schimmer works at CANTOR FITZGERALD and has 3 price targets and 2 ratings on NKTR

Which analyst is the currently most bullish on NKTR (Nektar Therapeutics)?

George Farmer with highest potential upside - $45.4

Which analyst is the currently most reserved on NKTR (Nektar Therapeutics)?

Roger Song with lowest potential downside - -$19.75

Nektar Therapeutics in the News

Why Nektar Therapeutics Stock Popped 6% on Friday

Key Points Investors were reacting to the biotech’s second-quarter earnings report. Revenue was higher than analysts expected, although the net loss was deeper than the consensus.10 stocks we like better than Nektar Therapeutics › BiotechNektar Therapeutics(NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market’s close on Thursday, and the investor reaction was strong...

Nektar (NKTR) Q2 Revenue Falls 52%

Key Points Net loss per share (GAAP) of $2.95 improved compared to Q2 2024. GAAP revenue fell 52.3% compared to Q2 2024, driven by the lack of product sales after the facility sale, but still exceeded consensus estimates. Positive clinical trial progress and FDA Fast Track designation for rezpegaldesleukin, with cash runway now extends into...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?